Temperature reduction in cultures of hGM-CSF-expressing CHO cells:: Effect on productivity and product quality

被引:86
作者
Bollati-Fogolín, M
Forno, G
Nimtz, M
Conradt, HS
Etcheverrigaray, M
Kratje, R
机构
[1] Univ Nacl Litoral, Lab Cultivos Celulares, Fac Bioquim & Ciencias Biol, Santa Fe, Argentina
[2] GBF, German Res Ctr Biotechnol, Sturct Biol & Prot Glycosylat, D-38124 Braunschweig, Germany
关键词
D O I
10.1021/bp049825t
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We have demonstrated that temperature reduction from 37 to 33degreesC in the culture of a CHO cell line producing recombinant human granulocyte macrophage colony stimulating factor (CHO-Kl-hGM-CSF) leads to a reduced growth rate, increased cell viability, improved cellular productivity, and decreased cell metabolism. In the present study, CHO-Kl-hGM-CSF cells were cultured in a hiphasic mode: first, a 37degreesC growth phase for achieving a high cell number, followed by a production phase where the culture temperature was shifted to 33degreesC. The maximum cell density was not affected after temperature reduction while cell viability remained above 80% for a further 3.7 days in the culture kept at the lower temperature, when compared to the control culture maintained at 37degreesC. Furthermore, the total rhGM-CSF production increased 6 times in the culture shifted to 33degreesC. Because the quality and hence the in vivo efficacy of a recombinant protein might be affected by numerous factors, we have analyzed the N- and O-glycosylation of the protein produced under both cell culture conditions using high-pH anion-exchange chromatography and complementary mass spectrometry techniques. The product quality data obtained from the purified protein preparations indicated that decreasing temperature had no significant effect on the rhGM-CSF glycosylation profiles, including the degree of terminal sialylation. Moreover, both preparations exhibited the same specific in vitro biological activity. These results revealed that the employed strategy had a positive effect on the cell specific productivity of CHO-K1-hGM-CSF cells without affecting product quality, representing a novel procedure for the rhGM-CSF production process.
引用
收藏
页码:17 / 21
页数:5
相关论文
共 22 条
[1]  
Andersen DC, 2000, BIOTECHNOL BIOENG, V70, P25, DOI 10.1002/1097-0290(20001005)70:1<25::AID-BIT4>3.0.CO
[2]  
2-Q
[3]   Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor [J].
Armitage, JO .
BLOOD, 1998, 92 (12) :4491-4508
[4]   RECOMBINANT HUMAN INTERFERON-GAMMA - DIFFERENCES IN GLYCOSYLATION AND PROTEOLYTIC PROCESSING LEAD TO HETEROGENEITY IN BATCH CULTURE [J].
CURLING, EMA ;
HAYTER, PM ;
BAINES, AJ ;
BULL, AT ;
GULL, K ;
STRANGE, PG ;
JENKINS, N .
BIOCHEMICAL JOURNAL, 1990, 272 (02) :333-337
[5]   Impact of temperature reduction and expression of yeast pyruvate carboxylase on hGM-CSF-producing CHO cells [J].
Fogolín, MB ;
Wagner, R ;
Etcheverrigaray, M ;
Kratje, R .
JOURNAL OF BIOTECHNOLOGY, 2004, 109 (1-2) :179-191
[6]   N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line [J].
Forno, G ;
Fogolin, MB ;
Oggero, M ;
Kratje, R ;
Etcheverrigaray, M ;
Conradt, HS ;
Nimtz, M .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2004, 271 (05) :907-919
[7]   Enhancement of productivity of recombinant α-amidating enzyme by low temperature culture [J].
Furukawa, K ;
Ohsuye, K .
CYTOTECHNOLOGY, 1999, 31 (1-2) :85-94
[8]   CHARACTERIZATION OF CHANGES IN THE GLYCOSYLATION PATTERN OF RECOMBINANT PROTEINS FROM BHK-21-CELLS DUE TO DIFFERENT CULTURE CONDITIONS [J].
GAWLITZEK, M ;
VALLEY, U ;
NIMTZ, M ;
WAGNER, R ;
CONRADT, HS .
JOURNAL OF BIOTECHNOLOGY, 1995, 42 (02) :117-131
[9]   Increased productivity of recombinant tissular plasminogen activator (t-PA) by butyrate and shift of temperature: a cell cycle phases analysis [J].
Hendrick, V ;
Winnepenninckx, P ;
Abdelkafi, C ;
Vandeputte, O ;
Cherlet, M ;
Marique, T ;
Renemann, G ;
Loa, A ;
Kretzmer, G ;
Werenne, J .
CYTOTECHNOLOGY, 2001, 36 (1-3) :71-83
[10]   CLINICAL PHARMACOKINETIC STUDIES OF A HUMAN HEMATOPOIETIC GROWTH-FACTOR, GM-CSF [J].
HOVGAARD, D ;
MORTENSEN, BT ;
SCHIFTER, S ;
NISSEN, NI .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (01) :45-49